secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001493152-23-040327
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma Q3 net loss $4.2M ($0.41/sh) vs $5.7M loss year ago; cash $29.7M
--------------------------------------------------------------------------------

- Net loss for Q3 2023 was $4.2M ($0.41 per share) compared with net loss of $5.7M ($0.70 per share) in Q3 2022.
- R&D expenses increased to $4.2M from $3.9M, driven by clinical advancement of CC-42344 and CDI-988 trials.
- Cash and equivalents $29.7M as of Sep 30, 2023, down from $37.1M at Dec 31, 2022; working capital $30.3M.
- Enrollment underway in Phase 1 trial for dual coronavirus-norovirus oral protease inhibitor CDI-988.
- Phase 2a human challenge trial for oral influenza A drug CC-42344 expected to begin dosing before year-end 2023; inhaled CC-42344 Phase 1 planned H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315223040327/0001493152-23-040327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315223040327/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer